You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR CHLORPROPAMIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for CHLORPROPAMIDE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004363 ↗ Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus Completed Northwestern University 1995-12-01 OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00004363 ↗ Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus Completed National Center for Research Resources (NCRR) 1995-12-01 OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00881543 ↗ "Effect of Dipeptidyl Peptidase IV After Diets in näive Type 2 Diabetic Patients" Completed University of Sao Paulo N/A 2009-06-01 The purpose of this study is to demonstrate the secretion of glucose, insulin, glucagon, C-peptide and lipid profile after isocaloric diets with different nutritional compounds (fat, protein and carbohydrate food) in drug näive tipo 2 patients.
NCT00881543 ↗ "Effect of Dipeptidyl Peptidase IV After Diets in näive Type 2 Diabetic Patients" Completed University of Sao Paulo General Hospital N/A 2009-06-01 The purpose of this study is to demonstrate the secretion of glucose, insulin, glucagon, C-peptide and lipid profile after isocaloric diets with different nutritional compounds (fat, protein and carbohydrate food) in drug näive tipo 2 patients.
NCT02456428 ↗ Incretin-based Drugs and the Risk of Heart Failure Completed Canadian Institutes of Health Research (CIHR) 2014-03-01 The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone or in combination with other anti-diabetic drugs are associated with an increased risk of heart failure (HF) compared to other combinations of oral hypoglycemic agents (OHA). The investigators will carry out separate population based cohort studies using administrative health databases in six jurisdictions in Canada, the US and the UK. Cohorts will be defined by the initiation of a new anti-diabetic drug when incretin-based drugs entered the market, with follow-up until hospitalization for HF. Analyses will be done separately for groups of patients with and without prior HF. The results from the separate sites will be combined to provide an overall assessment of the risk of HF in users of incretin-based drugs and by class of incretin-based drugs.
NCT02456428 ↗ Incretin-based Drugs and the Risk of Heart Failure Completed Drug Safety and Effectiveness Network, Canada 2014-03-01 The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone or in combination with other anti-diabetic drugs are associated with an increased risk of heart failure (HF) compared to other combinations of oral hypoglycemic agents (OHA). The investigators will carry out separate population based cohort studies using administrative health databases in six jurisdictions in Canada, the US and the UK. Cohorts will be defined by the initiation of a new anti-diabetic drug when incretin-based drugs entered the market, with follow-up until hospitalization for HF. Analyses will be done separately for groups of patients with and without prior HF. The results from the separate sites will be combined to provide an overall assessment of the risk of HF in users of incretin-based drugs and by class of incretin-based drugs.
NCT02456428 ↗ Incretin-based Drugs and the Risk of Heart Failure Completed Canadian Network for Observational Drug Effect Studies, CNODES 2014-03-01 The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone or in combination with other anti-diabetic drugs are associated with an increased risk of heart failure (HF) compared to other combinations of oral hypoglycemic agents (OHA). The investigators will carry out separate population based cohort studies using administrative health databases in six jurisdictions in Canada, the US and the UK. Cohorts will be defined by the initiation of a new anti-diabetic drug when incretin-based drugs entered the market, with follow-up until hospitalization for HF. Analyses will be done separately for groups of patients with and without prior HF. The results from the separate sites will be combined to provide an overall assessment of the risk of HF in users of incretin-based drugs and by class of incretin-based drugs.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for CHLORPROPAMIDE

Condition Name

Condition Name for CHLORPROPAMIDE
Intervention Trials
Diabetes Mellitus, Type 2 2
Diabetes Insipidus 1
Diabetes Insipidus, Neurohypophyseal 1
Diabetes Type 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for CHLORPROPAMIDE
Intervention Trials
Diabetes Mellitus, Type 2 4
Diabetes Mellitus 4
Diabetes Insipidus, Neurogenic 1
Diabetes Insipidus 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for CHLORPROPAMIDE

Trials by Country

Trials by Country for CHLORPROPAMIDE
Location Trials
Canada 3
United States 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for CHLORPROPAMIDE
Location Trials
Illinois 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for CHLORPROPAMIDE

Clinical Trial Phase

Clinical Trial Phase for CHLORPROPAMIDE
Clinical Trial Phase Trials
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for CHLORPROPAMIDE
Clinical Trial Phase Trials
Completed 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CHLORPROPAMIDE

Sponsor Name

Sponsor Name for CHLORPROPAMIDE
Sponsor Trials
Canadian Institutes of Health Research (CIHR) 3
Drug Safety and Effectiveness Network, Canada 3
Canadian Network for Observational Drug Effect Studies, CNODES 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for CHLORPROPAMIDE
Sponsor Trials
Other 12
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.